--- title: "Karyopharm Therap (KPTI.US) — Financial Reports" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/KPTI.US/norm.md" symbol: "KPTI.US" name: "Karyopharm Therap" parent: "https://longbridge.com/en/quote/KPTI.US.md" datetime: "2026-05-21T21:02:12.582Z" locales: - [en](https://longbridge.com/en/quote/KPTI.US/norm.md) - [zh-CN](https://longbridge.com/zh-CN/quote/KPTI.US/norm.md) - [zh-HK](https://longbridge.com/zh-HK/quote/KPTI.US/norm.md) --- # Karyopharm Therap (KPTI.US) — Financial Reports ## Income Statement (USD) | Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | | --- | --- | --- | --- | --- | --- | | EPS | -1.24 | -5.71 | -3.82 | -4.32 | -2.77 | | ROE | 32.07% | 145.43% | 52.15% | 67.00% | 47.89% | | Revenue | 35.07M | 34.08M | 44.04M | 37.93M | 30.02M | | Net income | -22.39M | -102.20M | -33.13M | -37.25M | -23.46M | | Operating income | -26.76M | -17.84M | -15.22M | -24.39M | -33.26M | | Gross margin | 96.16% | 14.46% | 25.85% | 10.78% | -19.67% | | Net margin | -63.86% | -299.89% | -75.21% | -98.22% | -78.17% | | Profit quality | - | - | - | - | - | ## Balance Sheet (USD) | Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | | --- | --- | --- | --- | --- | --- | | A&L | 131.42M | 108.42M | 96.23M | 104.88M | 127.71M | | Leverage | -0.4947 | -0.3701 | -0.3574 | -0.4390 | -0.6203 | | BVPS | -12.07 | -16.00 | -30.94 | -27.63 | -24.03 | | Turnover | 1.17 | 1.07 | 0.9977 | 0.8610 | 0.8557 | | Cash & STI | 90.85M | 63.74M | 45.88M | 51.70M | 69.94M | | Inv & Rec | - | 4.04M | 3.97M | 4.99M | 4.77M | | LT assets | - | 4.65M | 4.80M | 5.33M | 5.80M | | Net debt | 205.88M | 242.20M | 224.04M | 212.42M | 190.26M | ## Cash Flow Statement (USD) | Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | | --- | --- | --- | --- | --- | --- | | Operating CF | - | -11.83M | -5.86M | -18.70M | -38.98M | | Investing CF | - | 5.00M | 4.80M | 18.29M | 15.29M | | Financing CF | - | 29.69M | 0.0000 | 356000.00 | - | | Free CF | - | -6.17M | 2.10M | -5.14M | -22.08M | | OCF coverage | - | -4731.20% | - | - | - | | Repaid & issued | - | 27.25M | - | - | - | | CapEx | - | - | - | - | - |